Lung Cancer Europe shared a post on LinkedIn:
“Ivonescimab was one of the most talked-about drugs in lung cancer at ASCO 2026, largely on the back of the HARMONi-6 results.
The same drug is now being studied in Europe in a separate trial, HARMONi-7, as a possible first-line option for some people with non-small cell lung cancer whose tumours have high PD-L1 expression. Ivonescimab is investigational and is not approved by regulators in Europe.
More information, including which European countries currently have trial sites.
This is for awareness only. It is not medical advice or a recommendation. Whether any treatment or study is right for someone is a decision for that person and their own clinical team.”
Other articles about Lung Cancer Europe on OncoDaily.